NASDAQ · Drug Manufacturers - General · USD
Medicus Pharma Ltd. (MDCX) Stock Analysis
Medicus Pharma Ltd. (MDCX) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MDCX Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.77
- Previous Close
- $2.72
- Day's Range
- 2.67–2.91
- 52-Week Range
- 2.55–139.00
- Volume
- 30.70K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.30
Valuation
- Market Cap
- $3.84M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −119.00
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$35.44M
- Shares Outstanding
- 1.43M
- 1-Year Return
- −97.75%
Dividend and dates
- Avg Volume
- 105.53K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MDCX closed at $2.68, −97.75% over 1 year.
Medicus Pharma Ltd. (MDCX) has a market capitalization of $3.84M.
In fiscal 2025, MDCX reported revenue of $0.00.
MDCX Stock Return by Calendar Year
Medicus Pharma Ltd. (MDCX) return since Nov 2024: what $10,000 became
- 1 year
- $10,000 $225
- −97.75%
- Since Nov 2024
- $10,000 $202
- −97.98%
If you had invested $10,000 in Medicus Pharma Ltd. (MDCX) at the close on November 14, 2024, the earliest close on record here, it would have been worth $202 at the close on October 21, 2026: −97.98% in total, −86.71% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −96.50% |
| 2025 | −37.04% |
| 2024 (partial year) | −8.30% |
As of October 21, 2026.
MDCX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$35.44M | — |
| 2024 | $0.00 | −$11.16M | — |
| 2023 | $0.00 | −$5.31M | — |
| 2022 | $0.00 | −$1.69M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$34.36M | −$35.44M | — |
| 2024 | $0.00 | — | −$11.18M | −$11.16M | — |
| 2023 | $0.00 | — | −$2.66M | −$5.31M | — |
| 2022 | $0.00 | — | −$978.42K | −$1.69M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing
InvestorsHubMedicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Proactive InvestorsMedicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
YahooMedicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why
BenzingaMedicus Pharma Announces 50-For-1 Stock Split, Effective Oct. 12
BenzingaMedicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study
Yahoo
All 20 articles ↓Show fewer ↑
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Proactive InvestorsMedicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
YahooMedicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer
BenzingaMedicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Proactive InvestorsMedicus Pharma Optimizes Portfolio Strategy With High-Value Focus
YahooMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
YahooMedicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock
BenzingaMedicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Proactive InvestorsMedicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy
YahooMedicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study
InvestorsHubMedicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Proactive InvestorsMedicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
YahooMedicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings
BenzingaMedicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Proactive Investors
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
MRKMerck & Co., Inc.
$369.78B
NVSNovartis AG
$292.58B
AZNAstraZeneca PLC
$261.82B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$374.30B
TMOThermo Fisher Scientific Inc.
$256.61B
AMGNAmgen Inc.
$236.98B
GILDGilead Sciences, Inc.
$190.42B
ABTAbbott Laboratories
$173.92B